Table 2

Summary of the data collection per study’s stage

Stage 1Stage 2Stage 3
Sociodemographic and anthropometric characteristics×
Brief PA17 18 assessment××
Respiratory symptoms (wheeze, breathlessness)×××
Diagnosis of chronic respiratory disease×××
Comorbidities and allergies×××
Smoking habits and ETS××
A2 Score14×
Family history of asthma××
Age of asthma onset×
Inhaler prescription/use×
Mini-AQLQ29 30×
Signs of asthma×
Asthma control (according to GINA)××
Asthma pharmacological treatment××*
Inhalation technique×
Adherence to inhaled medication××*
Other treatments××
No of exacerbations××*
No of visits to emergency room××*
No of hospital admissions and length of hospital stay××*
No of unscheduled consultations××*
No of consultations primary care team××*
Referral for specialist care××*
Standard measurements (blood pressure, height, weight)×
Pre-BD and post-BD32 lung function×
Pulmonary diagnostic tests (previously performed)×
Peripheral blood eosinophil and neutrophil counts×
Use of health and fitness apps××
CARATm app use and opinion×
  • *In the previous 3 and 12 months.

  • A2 Score, A2 adult asthma score; CAPTURE, COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk; CARAT, Control of Allergic Rhinitis and Asthma Test; CARATm, Caracteristicas Auto-reportadas de Asma em Tecnologias Móveis; EQ-5D, European Quality of Life Five Dimension; ETS, Environmental tobacco smoke; FeNO, Fractional exhaled nitric oxide; Mini-AQLQ, Mini Asthma Quality of Life Questionnaire; mMRC, Modified British Medical Research Council; PA, Brief physical activity assessment; pre-BD and post-BD, Spirometry prebronchodilator and postbronchodilator.